These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 16280695)
1. Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks. Trottier B; Walmsley S; Reynes J; Piliero P; O'Hearn M; Nelson M; Montaner J; Lazzarin A; Lalezari J; Katlama C; Henry K; Cooper D; Clotet B; Arastéh K; Delfraissy JF; Stellbrink HJ; Lange J; Kuritzkes D; Eron JJ; Cohen C; Kinchelow T; Bertasso A; Labriola-Tompkins E; Shikhman A; Atkins B; Bourdeau L; Natale C; Hughes F; Chung J; Guimaraes D; Drobnes C; Bader-Weder S; Demasi R; Smiley L; Salgo MP J Acquir Immune Defic Syndr; 2005 Dec; 40(4):413-21. PubMed ID: 16280695 [TBL] [Abstract][Full Text] [Related]
2. A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults. Lalezari JP; DeJesus E; Northfelt DW; Richmond G; Wolfe P; Haubrich R; Henry D; Powderly W; Becker S; Thompson M; Valentine F; Wright D; Carlson M; Riddler S; Haas FF; DeMasi R; Sista PR; Salgo M; Delehanty J Antivir Ther; 2003 Aug; 8(4):279-87. PubMed ID: 14518696 [TBL] [Abstract][Full Text] [Related]
3. TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals. Reynes J; Arastéh K; Clotet B; Cohen C; Cooper DA; Delfraissy JF; Eron JJ; Henry K; Katlama C; Kuritzkes DR; Lalezari JP; Lange J; Lazzarin A; Montaner JS; Nelson M; O' Hearn M; Stellbrink HJ; Trottier B; Walmsley SL; Buss NE; Demasi R; Chung J; Donatacci L; Guimaraes D; Rowell L; Valentine A; Wilkinson M; Salgo MP AIDS Patient Care STDS; 2007 Aug; 21(8):533-43. PubMed ID: 17711378 [TBL] [Abstract][Full Text] [Related]
4. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. Lazzarin A; Clotet B; Cooper D; Reynes J; Arastéh K; Nelson M; Katlama C; Stellbrink HJ; Delfraissy JF; Lange J; Huson L; DeMasi R; Wat C; Delehanty J; Drobnes C; Salgo M; N Engl J Med; 2003 May; 348(22):2186-95. PubMed ID: 12773645 [TBL] [Abstract][Full Text] [Related]
5. Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. Nelson M; Arastéh K; Clotet B; Cooper DA; Henry K; Katlama C; Lalezari JP; Lazzarin A; Montaner JS; O'Hearn M; Piliero PJ; Reynes J; Trottier B; Walmsley SL; Cohen C; Eron JJ; Kuritzkes DR; Lange J; Stellbrink HJ; Delfraissy JF; Buss NE; Donatacci L; Wat C; Smiley L; Wilkinson M; Valentine A; Guimaraes D; Demasi R; Chung J; Salgo MP J Acquir Immune Defic Syndr; 2005 Dec; 40(4):404-12. PubMed ID: 16280694 [TBL] [Abstract][Full Text] [Related]
6. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. Lalezari JP; Henry K; O'Hearn M; Montaner JS; Piliero PJ; Trottier B; Walmsley S; Cohen C; Kuritzkes DR; Eron JJ; Chung J; DeMasi R; Donatacci L; Drobnes C; Delehanty J; Salgo M; N Engl J Med; 2003 May; 348(22):2175-85. PubMed ID: 12637625 [TBL] [Abstract][Full Text] [Related]
7. [Clinical efficacy and tolerance of enfuvirtide (Fuzeon), new antiretroviral inhibitors of intracellular penetration of human immunodeficiency virus (HIV) type 1]. Raffi F Med Mal Infect; 2004 Sep; 34 Spec No 1():8-17. PubMed ID: 15742550 [TBL] [Abstract][Full Text] [Related]
8. Switching from a toxicity-causing antiretroviral to enfuvirtide in patients with HIV: the SWITCH TOX study. Streinu-Cercel A; de Gorgolas M; Müller M; Portilla J; Rugina S; Böcher W; Staszewski S; Pulik P; Rowell L; Salgo M; Stoll M HIV Clin Trials; 2008; 9(6):375-86. PubMed ID: 19203903 [TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of enfuvirtide for 48 weeks as part of an optimized antiretroviral regimen in pediatric human immunodeficiency virus 1-infected patients. Wiznia A; Church J; Emmanuel P; Eppes S; Rowell L; Evans C; Bertasso A; Pediatr Infect Dis J; 2007 Sep; 26(9):799-805. PubMed ID: 17721374 [TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of enfuvirtide in combination with darunavir-ritonavir and an optimized background regimen in treatment-experienced human immunodeficiency virus-infected patients: the below the level of quantification study. DeJesus E; Gottlieb MS; Gathe JC; Greenberg ML; Guittari CJ; Zolopa AR Antimicrob Agents Chemother; 2008 Dec; 52(12):4315-9. PubMed ID: 18809940 [TBL] [Abstract][Full Text] [Related]
12. Enfuvirtide: a fusion inhibitor for the treatment of HIV infection. Fung HB; Guo Y Clin Ther; 2004 Mar; 26(3):352-78. PubMed ID: 15110129 [TBL] [Abstract][Full Text] [Related]
13. Health-related quality of life with enfuvirtide (ENF; T-20) in combination with an optimized background regimen. Cohen CJ; Clumeck N; Molina JM; Thompson M; Patel K; Wintfeld N; Green J J Acquir Immune Defic Syndr; 2004 Sep; 37(1):1140-6. PubMed ID: 15319673 [TBL] [Abstract][Full Text] [Related]
14. Postmarketing use of enfuvirtide in veterans: provider compliance with criteria for use, overall efficacy, and tolerability. Belperio PS; Mole LA; Halloran J; Boothroyd DB; Thomas IC; Backus LI Ann Pharmacother; 2008 Nov; 42(11):1573-80. PubMed ID: 18940919 [TBL] [Abstract][Full Text] [Related]
15. Consensus recommendation from a group of German experts for the use of enfuvirtide in heavily pretreated HIV patients. Salzberger B; Däumer M; Gute P; Jaeger H; Knechten H; van Lunzen J; Mauss S; Mayr C; Moll A; Plettenberg A; Rockstroh J; Staszewski S; Stellbrink HJ; Stoll M; Sturmer M Eur J Med Res; 2007 Mar; 12(3):93-102. PubMed ID: 17507306 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of switching from enfuvirtide to raltegravir in patients with virological suppression. Santos JR; Llibre JM; Ferrer E; Domingo P; Imaz A; Moltó J; Martin-Iguacel R; Caum C; Podzamczer D; Clotet B HIV Clin Trials; 2009; 10(6):432-8. PubMed ID: 20133273 [TBL] [Abstract][Full Text] [Related]
17. Enfuvirtide: first fusion inhibitor for treatment of HIV infection. Jamjian MC; McNicholl IR Am J Health Syst Pharm; 2004 Jun; 61(12):1242-7. PubMed ID: 15259753 [TBL] [Abstract][Full Text] [Related]
18. Virologic and immunologic impact and durability of enfuvirtide-based antiretroviral therapy in HIV-infected treatment-experienced patients in a clinical setting. Loutfy MR; Antoniou T; Shen S; Diong C; Vlaicu M; Halpenny R; Kovacs C; Fletcher D; Raboud JM HIV Clin Trials; 2007; 8(1):36-44. PubMed ID: 17434847 [TBL] [Abstract][Full Text] [Related]
19. Enfuvirtide in HIV-1-infected individuals changing therapy to a nucleoside reverse transcriptase inhibitor sparing regimen: the ALLIANCE Study. Dwyer DE; Workman C; Hales G; Amin J; Cooper D; Miller J; Antivir Ther; 2006; 11(4):409-19. PubMed ID: 16856614 [TBL] [Abstract][Full Text] [Related]
20. Utilizing a new class of antiretrovirals: role of fusion inhibitors in HIV disease management. Murphy RL AIDS Read; 2003 Dec; 13(12 Suppl Antiretroviral):S12-8. PubMed ID: 19960652 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]